Zhong Guo Jing Ji Wang·2025-12-04 06:41Core Viewpoint - Dongfang Biological (688298.SH) reported a slight increase in revenue for the first three quarters of 2025, but continued to face net losses, indicating ongoing financial challenges despite some improvements in cash flow [1]. Financial Performance - The company achieved an operating revenue of 672 million yuan in the first three quarters of 2025, representing a year-on-year increase of 2.16% [1]. - The net profit attributable to shareholders was -213 million yuan, an improvement from -262 million yuan in the same period last year [1]. - The net profit excluding non-recurring gains and losses was -232 million yuan, compared to -350 million yuan in the previous year [1]. - The net cash flow from operating activities was -155 million yuan, an improvement from -367 million yuan year-on-year [1]. Future Projections - For 2024, Dongfang Biological expects to achieve an operating revenue of 828 million yuan, a year-on-year growth of 0.95% [4]. - The projected net profit attributable to shareholders is -529 million yuan, worsening from -398 million yuan in the previous year [4]. - The net profit excluding non-recurring gains and losses is expected to be -571 million yuan, compared to -431 million yuan in the prior year [4]. - The net cash flow from operating activities is projected to be -348 million yuan, an improvement from -1.646 billion yuan in the previous year [4]. Capital Raising - Dongfang Biological raised a total of 637.5 million yuan from its public offering, with a net amount of 550.8 million yuan after expenses [5]. - The final net amount raised was 10.82 million yuan less than originally planned [5]. - The funds are intended for projects including the production of rapid diagnostic products, technology research and development, and the establishment of a marketing network [5].